These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23872910)

  • 21. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
    Takano M; Ikeda Y; Kudoh K; Kita T; Sasaki N; Kikuchi Y
    J Obstet Gynaecol Res; 2013 Apr; 39(4):872-5. PubMed ID: 23167774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
    Ekinci D; Kargi A; Yalcin AD; Savas B
    J BUON; 2013; 18(1):245-52. PubMed ID: 23613412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metronomic cyclophosphamide with cisplatin and bevacizumab: a new chemotherapeutic regimen for refractory anaplastic ependymoma.
    Lorgis V; Varbedian O; Ghiringhelli F
    Anticancer Res; 2012 Nov; 32(11):5067-70. PubMed ID: 23155280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Chura JC; Van Iseghem K; Downs LS; Carson LF; Judson PL
    Gynecol Oncol; 2007 Nov; 107(2):326-30. PubMed ID: 17706754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
    Martin L; Schilder R
    J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab in the treatment of ovarian cancer.
    Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
    Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [First line chemotherapy of epithelial cancers of the ovary].
    Lhommé C; Pautier P
    Rev Prat; 1997 Jun; 47(11):1205-10. PubMed ID: 9238816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms.
    Bidus MA; Webb JC; Seidman JD; Rose GS; Boice CR; Elkas JC
    Gynecol Oncol; 2006 Jul; 102(1):5-7. PubMed ID: 16697451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment strategies in ovarian cancer].
    Puistola U; Leminen A
    Duodecim; 2013; 129(18):1917-24. PubMed ID: 24187783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical experience of single agent bevacizumab in relapsing ovarian cancer.
    Emile G; Chauvenet L; Tigaud JM; Chidiac J; Pujade Lauraine E; Alexandre J
    Gynecol Oncol; 2013 Jun; 129(3):459-62. PubMed ID: 23474345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.